This Setup Cleared Two Filters — And Our Engine Re-Entered

What the system saw

We keep coming back to CRNX. That's not an accident. The Relative Strength Engine has flagged this name seven times in the last few weeks, and here we are again — a fresh entry at $84.70, right off the 20-day moving average. When a stock sits in the 96th percentile of relative strength over the past 63 trading days and keeps finding buyers exactly where the chart says it should, the system pays attention. It paid attention again today. The stock closed Tuesday at $84.69, barely moved overnight, and touched $84.70 on the open. That's not a breakout — it's more like the market shrugging and holding the line. Sometimes that quiet act of holding is the whole signal.

Why our Relative Strength Engine liked it

The Relative Strength Engine hunts for names that are outperforming the broad market over a multi-month window, then pulling back just enough to reset without breaking. CRNX clears both bars. It sits in the top 4% of names we track on a 63-day RS lookback, resting within a fraction of a percent of its 20dma right now — not below it, not bouncing off a low, just leaning on it. The 'volume dry-up' component of the score also fired, which suggests the recent consolidation is passive sellers stepping away, not active distribution. That's a meaningfully different thing. One honest caveat on the fundamentals: CRNX is a pre-profitability biotech. Negative earnings, negative ROE, a DCF that doesn't work in any traditional sense. The analyst consensus is Buy, but the average price target sits at $84.86 — essentially where the stock trades right now. This setup is entirely a price-action and relative-strength story. We're not holding it for a revaluation thesis.

The trade plan

Entry is $84.70. Stop is $83.75 — that's $0.95 of risk per share, just below the 20dma and the day's low. Our system's 2R target is $86.61. We're putting about $4,997 behind this one, which works out to 59 shares in the paper account. The math is clean: if we're wrong and get stopped out, we lose roughly $56 on the position. If the setup plays out to target, we're looking at just under $113 on the same 59 shares. That's the 2R structure in action — the target is always twice the dollar risk, no exceptions.

Position size: our paper account is putting about $4,997 (59 shares) into this trade, sized to risk roughly $56 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

A few things worth saying plainly. This is the seventh CRNX entry in recent weeks, which means the paper account carries real concentration in a single biotech name. That's not a catastrophic risk given the position sizing, but it's not invisible either. The 20dma has held as support each time so far — and we don't know when that stops working. Conviction score on this signal came in at 67.5 out of 100, which is mid-tier for us — not our highest-confidence setup. The broader experiment is also sitting at a 0% win rate on closed trades through Day 33, with all the gains currently living in open positions. The system is up 1.7% while SPY gained 2.4% over the same window. We're trailing the index right now, and that's worth keeping in front of you.

One more thought before we go

The real question isn't whether CRNX holds $84.70 today — it's whether all these open positions convert into closed winners or slowly give back their gains. We'll find out. The system keeps doing exactly what it's designed to do. The scoreboard will eventually catch up with the thesis, one way or the other.